Clinical trials: Pharmacokinetics of Metformin
Diabetes Mellitus Type 2
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5095932 in adult patients with type 2 diabetes mellitus.
- Trial name
- NCT01017302
- Testing
- RO5095932
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients
The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics (PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.
- Trial name
- NCT01103622
- Testing
- AZD1656, Digoxin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Healthy
Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers
Metformin Glycinate is a novel biguanide compound developed as a potential candidate for the treatment of type 2 diabetes. Metformin Glycinate was found to improve metabolic control in naive patients with type 2 diabetes.
- Trial name
- NTC00940472 (NCT01560481)
- Testing
- Step A: metformin glycinate 620 mg single dose, Step A: metformin glycinate 1240 mg single dose, Step A: metformin glycinate 2480 mg single dose
- Where
- Spain
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Bioequivalance
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC004 (NCT07763951)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Diabetes Mellitus, Type 2
An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions
The aim of this study is to demonstrate bioequivalence of fixed dose combination Dapagliflozin + Metformin modified -release, film-coated tablets, 10 mg + 1000 mg, (AstraZeneca AB, Sweden) versus Forxiga™ (Dapagliflozin)…
- Trial name
- NCT02722239
- Testing
- Xigduo XR, Metformin ER (Glucophage® long), Dapagliflozin (Forxiga)
- Where
- Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Elderly
Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in the Elderly
This study aims to investigate the pharmacokinetics/pharmacodynamics metformin IR after oral administration in healthy elderly male volunteers.
- Trial name
- ME01 (NCT02125305)
- Testing
- Metformin
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy Volunteers
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy…
- Trial name
- NCT07446400
- Testing
- Repinatrabit, EE/NE, Metformin
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Neuropathic Pain
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
The primary objective was to investigate whether multiple-dose administration of eslicarbazepine acetate affects the pharmacokinetics of metformin.
- Trial name
- NCT00971295
- Testing
- Metformin, Eslicarbazepine acetate
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Diabetes, Diabetes Mellitus, Type 2
Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects
This trial is conducted in Europe and Asia. The aim of the trial is to investigate the influence of semaglutide on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02022254
- Testing
- semaglutide, metformin, warfarin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.
- Trial name
- NCT01119846
- Testing
- GSK1292263, Sitagliptin
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the Body
The main objective of this trial is to investigate the effect of BI 730357 under steady state conditions on the pharmacokinetics of digoxin, furosemide, metformin and rosuvastatin given as a cocktail (Reference, R: cocktail…
- Trial name
- NCT04590937
- Testing
- BI 730357, CRESTOR®, Lenoxin®
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin
To assess the pharmacokinetics of AZD1656 during coadministration with Simvastatin.
- Trial name
- NCT01096940
- Testing
- AZD1656, simvastatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and pharmacokinetics of double-blind S-707106 alone and in combination with open-label metformin in patients with type 2 diabetes mellitus
- Trial name
- NCT01154348
- Testing
- S-707106, Metformin, S-707106 plus metformin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Shionogi
Heart Failure, Systolic
Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography
The purpose of the study is to evaluate if metformin is taken up into the failing myocardium. Recent experimental and epidemiological studies have shown beneficial effects of metformin on heart failure.
- Trial name
- NCT03122769
- Testing
- 11C-metformin
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Henrik Wiggers
Rheumatoid Arthritis
Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers
This study will evaluate the potential effect of CP 690,550 on the pharmacokinetics of metformin, a probe drug for organic cationic transport.
- Trial name
- NCT01405118
- Testing
- Metformin/CP-690,550
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin
Assess the safety and tolerability of once daily oral doses of BI 187004 in patients with type 2 diabetes mellitus without oral antidiabetic treatment and in patients on a stable metformin background treatment over 28 days.
- Trial name
- NCT02150824
- Testing
- BI 187004
- Where
- 3 sites in Germany
- Volunteers
- 103 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
The purpose of this study is to evaluate the effect of steady-state ranolazine on the steady state PK of metformin in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01546597
- Testing
- Metformin, Ranolazine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus Type 2
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to test the safety and pharmacodynamics of an oral formulation of insulin in subjects with Type 2 Diabetes.
- Trial name
- NCT01889667
- Testing
- ORMD-0801 Dose # 1, ORMD-0801 Dose # 2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oramed, Ltd.
Type 1 Diabetes, Obesity
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications.
- Trial name
- NCT05414409
- Testing
- Metformin
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Heba M. Ismail
Pharmacokinetics
Fed Bioequivalence Study of 2 Metformin 500 mg Prolongued Release Tablets in 28 Healthy Male and Female Volunteers
The objective of the study is to compare the bioavailability of the Test and Reference products both containing Metformin 500 mg prolonged release tablets (MFM) in healthy male and female volunteers under fed conditions and to…
- Trial name
- NCT05124717
- Testing
- Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine), Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
- Where
- Czechia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Joint Stock Company "Farmak"